The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

IBRX FINANCIAL STATEMENTS

Immunitybio Inc — balance sheet, income statement and cash flow trends

IBRXImmunitybio Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-1 B-500 M0202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue165.8 M $Gross Profit156.9 M $ · 95%Operating Income-251.8 M $ · -152%Pre-tax Income-992.6 M $ · -599%Net Income to Owners-992.4 M $ · -599%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue165.8 M $+192.9%
Gross Profit156.9 M $+178.1%
Operating Income-251.8 M $—
EBITDA-888.3 M $—
Net Income to Owners-992.4 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
-1 B01 B202120222023202420252026

Capital Structure

Q2 2026
Total Assets628.5 M
  • Current Liabilities76.7 M $5%
  • Long-term Liabilities1.6 B $95%

Key Figures

YoY change
Total Assets628.5 M $+56.3%
Total Liabilities1.7 B $+72.3%
Total Equity-1 B $—
Cash & ST Investments357.4 M $+132.6%
Total Debt38.7 M $-92.8%
Net Debt-37 M $-109.3%

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-400 M-200 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-600 M-400 M-200 M0-356.5 M $Operating-308.6 M $Investing720.7 M $Financing55.7 M $Net Change

Key Figures

YoY change
Operating Cash Flow-356.5 M $—
Capital Expenditures9.1 M $+28.5%
Free Cash Flow-365.6 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on IBRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 3, 26. This content is for informational purposes only and is not investment advice.